The global Asthma and COPD Drugs Market is witnessing sustained growth as healthcare systems intensify efforts to address chronic respiratory diseases through innovative therapies and improved patient management strategies. “According to a recent study by SNS Insider, the global Asthma and COPD Drugs Market size valued at USD 33.16 billion in 2025, is anticipated to grow to USD 56.21 billion by 2035, registering a CAGR of 5.42% over the 2026–2035 forecast period.”
An increase in pollution levels, aging demographics, smoking, and shifts in lifestyle have increased the number of people in need of prolonged treatment for respiratory conditions. The pharmaceutical industry is increasing its repertoire of drugs through innovative inhalers, biologicals, and digital technologies, which enhance patient compliance and tailor treatment of asthma and chronic obstructive pulmonary disease (COPD) patients.
To Get Detailed Insights on the Asthma and COPD Drugs Market – Request a Sample Report
Respiratory Disease Burden Encourages Next-Generation Treatment Development
Healthcare professionals have also been moving away from emergency treatment towards disease prevention in the field of healthcare. Monitoring, diagnosing at an early stage, and administering maintenance drugs are some of the key elements in managing respiratory diseases, thus promoting the use of new medications.
This trend is also evident in global statistics on health. In 2025, there were over 600 million people suffering from asthma or COPD, and COPD was the third leading cause of mortality in the world, which claimed 3.2 million lives each year. Such figures also speed up the development of new long-acting bronchodilators, biological drugs, and combination inhalers.
Key Market Findings Highlight Strong Segment Expansion
Bronchodilators remained the leading drug category, representing 44.80% of market revenue in 2025 due to their widespread use in relieving airway obstruction. Meanwhile, combined therapies are expected to register the fastest growth, advancing at a 10.60% CAGR through 2035 as healthcare providers increasingly recommend integrated treatment approaches.
Prescription (Rx) medicines accounted for 71.25% of total revenue in 2025, supported by physician-guided treatment for chronic respiratory disorders. At the same time, over-the-counter (OTC) respiratory medications are projected to expand at a 9.20% CAGR, reflecting growing consumer awareness and easier access to symptom management solutions.
COPD represented the largest disease segment with a 58.40% market share during 2025 due to its high prevalence among aging populations and smokers. Asthma is expected to deliver the strongest future growth with a projected 8.90% CAGR, driven by rising diagnosis rates and broader availability of advanced therapies.
Retail pharmacies generated 48.75% of overall market revenue in 2025 by maintaining extensive distribution networks globally. Online pharmacies are forecast to emerge as the fastest-growing channel, recording an 11.10% CAGR as digital healthcare platforms and home delivery services gain wider acceptance.
Smart Inhalers and Precision Medicine Reshape Respiratory Care
Digital transformation has not ceased affecting the management of respiratory diseases. Smart inhalers, which have the ability to monitor and track adherence, are enabling doctors to better manage treatment and increase patients' adherence.
The adoption rate within the industry is rapidly growing. In 2025, the percentage of newly prescribed inhalers in the United States and Europe that used digital technologies exceeded 40%. Smart inhalers proved effective in improving adherence by 30% to 50%, which provides further potential for the development of comprehensive solutions by pharmaceutical companies. Increased funding in biologics designed for certain inflammatory processes contributes to personalized therapy for severely ill patients.
Regional Markets Maintain Strong Growth Momentum
North America contributed 36.58% of the global market revenue in 2025 due to high levels of development in the healthcare infrastructure and reimbursement, excellent pharmaceutical R&D capacities, and quick adoption of biological drugs and intelligent inhalers. The U.S., which is the largest market contributor in North America, is valued at USD 8.56 billion in 2025, growing at 5.07% CAGR to reach USD 14.04 billion by 2035.
Asia Pacific region will see the fastest growth during the forecast period, growing at a CAGR of 5.96% until 2035. Urbanization, poor air quality, increased cases of smoking, improved healthcare facilities, and government campaigns for promoting breathing issues will contribute to the growing demands in India, Japan, South Korea and many other countries.
Leading Companies Continue Advancing Respiratory Innovation
Competition across the global market remains focused on expanding biologic portfolios, improving inhalation technologies, and integrating digital health capabilities into respiratory treatment. Strategic collaborations, regulatory approvals, and investments in precision medicine continue to reshape product development pipelines.
Major companies operating in the global Asthma and COPD Drugs Market include AstraZeneca PLC, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC (GSK), Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., Sanofi SA, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd, Chiesi Farmaceutici SpA, Azurity Pharmaceuticals Inc., Grifols SA, Viatris Inc., Cipla Ltd, Orion Corporation, Regeneron Pharmaceuticals Inc., Amgen Inc., Sun Pharmaceutical Industries Limited, Theravance Biopharma Inc., and Verona Pharma PLC.
An SNS Insider analyst Parry Kardani commented, "The respiratory therapeutics landscape is entering a new phase driven by precision medicine, digital healthcare integration, and expanding biologic innovation. Companies capable of delivering accessible, technology-enabled treatments that improve long-term disease management will be well positioned to capture future opportunities as respiratory disease prevalence continues to rise worldwide.
About the Author
Get in touch
